August 16th, 2025The CS Foundation is working with NORD: National Organization for Rare Diseases to develop a Patient Registry / Natural History Study which was launched on March 1, 2023. The Chondrosarcoma Patient Registry is a platform for patients around the...
Read ArticleJune 28th, 2025USA Pickleball is the National Governing body for the sport of pickleball in the US. It provides players with official rules, tournaments, rankings and promotional materials. Jamie Elliott, a pickleball champion, an ambassador to USA Pickleball and...
Read ArticleMay 19th, 2025Video Tribute to Mike Snyder We invite you to watch a video tribute to Mike Snyder, who passed away on April 26. Description: Mike Snyder a Founding board member of the Chondrosarcoma Foundation shares his life journey, challenges with this ultra...
Read ArticleMay 12th, 2025The Chondrosarcoma (CS) Foundation will commemorate its fifth anniversary by continuing to educate the public about this rare bone cancer, advocate for patients fighting the disease and will report on their global natural history study. On May...
Read ArticleMay 1st, 2025It is with a broken heart that I report to you the passing of my dear friend and founding foundation board member: Mike Snyder. In his case it was not chondrosarcoma that took his life but he passed away from a second heart attack this past...
Read ArticleApril 11th, 2025John Gross, M.D. is a Faculty Associate professor, and bone and soft tissue surgical pathologist at Johns Hopkins University in Baltimore, Maryland. He is also one of the founding board members of the Chondrosarcoma Foundation and has been...
Read ArticleMarch 27th, 2025Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets Michael J. Wagner, MD; Erica M. Pimenta, MD, PhD1 ; Nathan W. Sweeney, PhD ; Elizabeth T. Loggers, MD, PhD; Jesse L. Roberts, MD; Elyse Brinkman, MD; Eleanor Y. Chen,...
Read ArticleMarch 18th, 2025Servier Pharmaceuticals has initiated a Phase 3 Clinical Trial for Ivosidenib, an IDH1 biomarker inhibitor. Their clinical trial is for patients diagnosed with conventional chondrosarcoma with advanced metastasis. There are about 30 sites globally...
Read Article